公开(公告)号：US20080118576A1

公开(公告)日：2008-05-22

申请号：US11846340

申请日：2007-08-28

申请人： Dan Theodorescu ,  Jae Kyun Lee

发明人： Dan Theodorescu ,  Jae Kyun Lee

IPC分类号： C40B30/02 ,  A61K31/7072 ,  A61K33/26 ,  A61K31/337 ,  A61P35/00

CPC分类号： A61K31/7072 ,  A61K31/337 ,  A61K45/06 ,  G16B20/00 ,  G16B25/00 ,  G16B40/00 ,  A61K2300/00

摘要： The present invention relates to a novel algorithm that uses molecular profile signatures to extrapolate the physiological processes of one type of cell set (e.g., cell line, tissue, normal or diseased) to predict the activity of an agent or agents against another type of cell set that has never been exposed to the agent in question (drug efficacy prediction). The novel algorithm also allows one to predict the therapeutic response of a patient to a therapeutic regimen even though the patient (or patients) may have never been exposed to that agent before, thereby allowing for selecting a therapeutic agent or combination of agents that would best suit the patient (i.e., personalized medicine). The present invention also relates to methods of using the agents identified by the novel algorithm to treat a variety of diseases, including cancer.

摘要翻译： 本发明涉及一种使用分子轮廓特征推断一种类型的细胞集（例如，细胞系，组织，正常或患病）的生理过程以预测试剂或试剂对另一类型细胞的活性的新算法 设定从未暴露于有关药物（药物效力预测）。 即使患者（或患者）可能从未暴露于该药物，从而允许选择最佳的治疗剂或药物组合，该新颖算法还允许人们预测患者对治疗方案的治疗反应 适合患者（即个性化医学）。 本发明还涉及使用由新算法鉴定的药物来治疗各种疾病（包括癌症）的方法。

公开(公告)号：US20130295590A1

公开(公告)日：2013-11-07

申请号：US13885376

申请日：2011-11-08

申请人： David Degraff ,  Robert Matusik ,  Peter Clark ,  Dan Theodorescu

发明人： David Degraff ,  Robert Matusik ,  Peter Clark ,  Dan Theodorescu

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N33/57407 ,  G01N2333/4703 ,  G01N2800/52 ,  G01N2800/56

摘要： The present invention provides for a proteomic approach to predicting, diagnosing and staging invasive bladder cancer, and for predicting patient survival and therapeutic efficacy. More specifically, the target being analyzed for reduced expression is FOXA1, and optionally including analysis of increased FOXA2 expression.

摘要翻译： 本发明提供了用于预测，诊断和分期侵袭性膀胱癌以及用于预测患者存活和治疗功效的蛋白质组学方法。 更具体地，被分析用于降低表达的靶是FOXA1，并且可选地包括增加的FOXA2表达的分析。